Biotechnology News and Research

RSS

Harvard's Wyss Institute completes first clinical study of new rapid neuroassessment device

Doctors routinely track their patients' hand-eye coordination to monitor any neuromuscular deficits, particularly as patients age or when they are injured -- but the tests they have been using to track this kind of information may be subjective and qualitative.

10 Feb 2013

Biogen Idec, Sobi release data from rFVIIIFc and rFIXFc phase 3 trials on hemophilia

Biogen Idec and Swedish Orphan Biovitrum (Sobi) released data that confirmed the ability of investigational recombinant factors VIII Fc fusion protein (rFVIIIFc) and IX Fc fusion protein (rFIXFc) to provide long-lasting protection from bleeding with fewer injections than are required with the current standard of care for people with hemophilia.

10 Feb 2013

Decade Sunshine, 3SBio enter Merger Agreement

3SBio Inc., a leading China-based biotechnology company focused on researching, developing, manufacturing and marketing biopharmaceutical products, today announced that it has entered into an agreement and plan of merger with Decade Sunshine Limited, an exempted company with limited liability incorporated under the laws of the Cayman Islands, and Decade Sunshine Merger Sub, an exempted company with limited liability incorporated under the laws of the Cayman Islands and a direct wholly owned subsidiary of Parent.

10 Feb 2013

Single gene therapy session can cure diabetes

Researchers from the Universitat Aut-noma de Barcelona (UAB), led by F-tima Bosch, have shown for the first time that it is possible to cure diabetes in large animals with a single session of gene therapy. As published this week in Diabetes, the principal journal for research on the disease, after a single gene therapy session, the dogs recover their health and no longer show symptoms of the disease.

10 Feb 2013

Positive data from Oncolytics' REOLYSIN Phase 2 combination trial on SCCLC

Oncolytics Biotech Inc. today announced results examining percent overall tumour shrinkage data from its U.S. Phase 2 clinical trial in patients with squamous cell carcinoma of the lung (SCCLC) using intravenous administration of REOLYSIN in combination with carboplatin and paclitaxel (REO 021).

9 Feb 2013

Investigators discover two new genes associated with severe early-onset disorders of heart rhythm

A team led by Vanderbilt University investigators has discovered two new genes - both coding for the signaling protein calmodulin - associated with severe early-onset disorders of heart rhythm.

7 Feb 2013

Society of Toxicology's 52nd Annual Meeting to be held from Mar. 10-16 in San Antonio

A group of 7,000 scientists working in multiple specialties, from more than 50 countries, will meet March 10-14, 2013 at the Henry B. Gonzalez Convention Center in San Antonio, Texas, to share their latest findings on 60 topical issues of concern to human health and the environment.

7 Feb 2013

Seattle Genetics commences two SGN-CD19A phase I trials in hematologic malignancies

Seattle Genetics, Inc. today announced the initiation of two phase I clinical trials of SGN-CD19A, one for patients with B-cell acute lymphoblastic leukemia (ALL) and one for patients with B-cell non-Hodgkin lymphomas.

6 Feb 2013

Arzeda, INVISTA partner to develop new technologies to enable novel bio-derived processes

INVISTA Technologies S.à r.l. and Arzeda Corp. announce a collaboration for the development of new technologies to enable novel bio-derived processes.

6 Feb 2013

More than £6M funding awarded to enhance development of biopharmaceuticals

More than £6M of funding has been awarded to enhance the development of biopharmaceuticals. In total £6.5M will fund 12 projects to deliver commercially important results, such as industrial-scale production of antibodies, stem cell preservation at room temperature, biopharmaceutical production using microbes and commercial scale stem cell therapy.

6 Feb 2013

Elan agrees to restructure Tysabri collaboration with Biogen Idec

Elan Corporation, plc today announced that it has agreed to restructure the Tysabri® collaboration with Biogen Idec.

6 Feb 2013

Teva initiates enrollment in AZILECT Phase IV clinical study for PD-MCI

Teva Pharmaceutical Industries Ltd. announced today enrollment of the first patient in the MODERATO study - a Phase IV clinical study designed to evaluate the effect of AZILECT (rasagiline tablets) on cognitive function in adults with mild cognitive impairment (MCI) in Parkinson's disease (PD-MCI).

6 Feb 2013

Viral conjunctivitis: potential new treatment

Viral conjunctivitis is a highly contagious infection, often causing major ophthalmic epidemics. There is no approved acute treatment currently approved by the FDA for viral conjunctivitis. A safe broad-spectrum antiviral agent is needed to treat this unmet medical need.

5 Feb 2013

Fabrinet second quarter total revenue increases 73.3% to $167.4 million

Fabrinet, a leading provider of advanced optical packaging and precision optical, electro-mechanical and electronic manufacturing services to original equipment manufacturers of complex products, today announced its financial results for the second quarter of fiscal 2013 ended December 28, 2012.

5 Feb 2013

AIBioTech announces implementation of L-asparaginase activity assay for pediatric ALL

AIBioTech is pleased to announce implementation of a new laboratory derived test to measure L-asparaginase levels in patients being treated with any of the current asparaginase drugs including: Oncaspar, Kidrolase, Erwinaze, and Elspar.

5 Feb 2013

BrainStorm initiates NurOwn Phase IIa dose-escalating trial in ALS

BrainStorm Cell Therapeutics, a leading developer of adult stem cell technologies for neurodegenerative diseases, announced today that the first patient began treatment in the Company's Phase IIa dose-escalating clinical trial for ALS.

5 Feb 2013

GVK Biosciences extends GOBIOM license to Biomarker Qualification Group of US FDA

GVK Biosciences (GVK BIO) today announced that it is extending its Clinical Biomarker Database (GOBIOM) license to the Biomarker Qualification Group of the US Food and Drug Administration (US FDA).

5 Feb 2013

Luminex consolidated fourth quarter revenue increases 16% to $55.5 million

Luminex Corporation today announced financial results for the fourth quarter and year ended December 31, 2012.

From Luminex 4 Feb 2013

Life Technologies full year 2012 revenue increases 2% to $3.8 billion

Life Technologies Corporation today announced results for its fourth quarter for the year ended Dec. 31, 2012.

4 Feb 2013

Scientists receive honorary doctorate for research on Alzheimer's disease

On Monday 4 February, Dennis J. Selkoe and five other "brain teasers" will receive an honorary doctorate from the KU Leuven. The promoters for this honorary doctorate - VIB-KU Leuven professors Bart De Strooper and Wim Robberecht - will honor Dennis J. Selkoe for his scientific insights, but also for his relentless search for new medicines to treat Alzheimer's Disease and other conditions that cause severe damage in the brain.

4 Feb 2013

Biotechnology News and Research

Harvard's Wyss Institute completes first clinical study of new rapid neuroassessment device

Biogen Idec, Sobi release data from rFVIIIFc and rFIXFc phase 3 trials on hemophilia

Decade Sunshine, 3SBio enter Merger Agreement

Single gene therapy session can cure diabetes

Positive data from Oncolytics' REOLYSIN Phase 2 combination trial on SCCLC

Investigators discover two new genes associated with severe early-onset disorders of heart rhythm

Society of Toxicology's 52nd Annual Meeting to be held from Mar. 10-16 in San Antonio

Seattle Genetics commences two SGN-CD19A phase I trials in hematologic malignancies

Arzeda, INVISTA partner to develop new technologies to enable novel bio-derived processes

More than £6M funding awarded to enhance development of biopharmaceuticals

Elan agrees to restructure Tysabri collaboration with Biogen Idec

Teva initiates enrollment in AZILECT Phase IV clinical study for PD-MCI

Viral conjunctivitis: potential new treatment

Fabrinet second quarter total revenue increases 73.3% to $167.4 million

AIBioTech announces implementation of L-asparaginase activity assay for pediatric ALL

BrainStorm initiates NurOwn Phase IIa dose-escalating trial in ALS

GVK Biosciences extends GOBIOM license to Biomarker Qualification Group of US FDA

Luminex consolidated fourth quarter revenue increases 16% to $55.5 million

Life Technologies full year 2012 revenue increases 2% to $3.8 billion

Scientists receive honorary doctorate for research on Alzheimer's disease

Event guide: 3rd IMPACCT Real World Evidence Summit Europe eBook

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Latest News